Day: January 30, 2026

Follow-on order of approximately $150,000 validates Actelis’ solution and demonstrates growing adoption in energy sector; deployment supports homeland security objectives through modernization of critical infrastructure monitoring and cyber-hardened connectivity SUNNYVALE, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it has received an expansion order of approximately $150,000 from the major European natural gas transmission system operator with whom it announced its initial deployment in October 2023. This significant follow-on order demonstrates customer satisfaction and further validates Actelis’ technology...

WISeSat.Space Brought Together Global Thought-Leaders to Davos to Address Quantum Security in Space Watch the entire roundtable discussion here: https://youtu.be/YDKj1nxbPdoDavos, Switzerland – January 30, 2026 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announced that during its Quantum Security Space Roundtable, held as part of the WISeKey Davos 2026 program, brought together thought-leaders from a variety of industries including defense, space, quantum technologies, and cybersecurity, to address one of the most urgent challenges facing the space sector: securing space infrastructure in the post-quantum era. As quantum computing advances, traditional cryptographic systems such as RSA and ECC will become vulnerable, placing satellite communications,...

VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care NEW YORK and STRONGSVILLE, Ohio, Jan. 30, 2026 (GLOBE NEWSWIRE) — Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations. Through this real-world evaluation collaboration, VIO Med Spa will conduct a structured, multi-site assessment of Obagi®...

Expanded Distribution Builds on Existing Relationship and Strengthens Regional Retail Presence BELVIDERE, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that its Gourmet Greens Hydroponic Basil is now available at Hannaford Supermarkets. The launch expands the Company’s branded product offerings within the retailer and builds on an established relationship focused on freshness, quality, and operational efficiency. Gourmet Greens is a distinct brand within Edible Garden’s portfolio, offering consumers premium hydroponically grown basil cultivated using the Company’s proprietary growing systems and sustainability-driven...

STAMFORD, Conn., Jan. 30, 2026 (GLOBE NEWSWIRE) — Star Group, L.P. (the “Company” or “Star”) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2026 first quarter results after the close of trading on February 4, 2026. Members of Star’s management team will host a webcast and conference call at 11:00 a.m. Eastern Time the following day, February 5, 2026, to review the three months ended December 31, 2025. The webcast will be accessible on the company’s website, at www.stargrouplp.com, and the telephone number for the conference call is 888-346-3470 (412-317-5169 for international callers). About Star Group, L.P.Star Group, L.P. is a full service provider specializing in the sale of home heating products and services to residential and commercial customers...

– Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – – Full data set submitted for presentation at an upcoming scientific conference – SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced new data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ ZIIHERA® (zanidatamab-hrii) in heavily pretreated patients with metastatic breast cancer (mBC). The topline findings, from an exploratory...

SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a...

Raymond James engaged as financial advisor Reduction in force implementedNEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the company explores strategic alternatives. About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...